Exelixis, Inc. $EXEL Stock: Vise Technologies Inc. Boosts Stake

Vise Technologies Inc. lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 73.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,248 shares of the biotechnology company’s stock after purchasing an additional 11,540 shares during the period. Vise Technologies Inc.’s holdings in Exelixis were worth $1,592,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Private Client Services LLC grew its stake in shares of Exelixis by 0.7% in the third quarter. Private Client Services LLC now owns 28,539 shares of the biotechnology company’s stock valued at $1,667,000 after buying an additional 209 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in Exelixis by 0.5% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 59,420 shares of the biotechnology company’s stock valued at $2,549,000 after acquiring an additional 281 shares during the last quarter. Brindle & Bay Financial Advisors LLC lifted its stake in Exelixis by 8.0% in the third quarter. Brindle & Bay Financial Advisors LLC now owns 4,105 shares of the biotechnology company’s stock valued at $240,000 after acquiring an additional 305 shares during the last quarter. Soltis Investment Advisors LLC lifted its stake in Exelixis by 7.0% in the third quarter. Soltis Investment Advisors LLC now owns 4,868 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 320 shares during the last quarter. Finally, Mather Group LLC. grew its position in shares of Exelixis by 124.6% in the 3rd quarter. Mather Group LLC. now owns 757 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 420 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Insider Activity

In other news, Director Mary Beckerle sold 9,812 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares of the company’s stock, valued at approximately $862,799.14. The trade was a 37.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 2.60% of the company’s stock.

Exelixis Price Performance

NASDAQ:EXEL traded up $0.86 during trading hours on Friday, reaching $69.57. 2,003,585 shares of the company were exchanged, compared to its average volume of 2,563,320. Exelixis, Inc. has a 1-year low of $39.71 and a 1-year high of $73.69. The company has a market capitalization of $16.98 billion, a P/E ratio of 20.83, a P/E/G ratio of 1.94 and a beta of 0.45. The business has a 50 day moving average of $60.92 and a 200 day moving average of $51.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.05. The business had revenue of $658.70 million during the quarter, compared to analysts’ expectations of $646.51 million. Exelixis had a net margin of 35.45% and a return on equity of 45.54%. Exelixis’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 earnings per share. As a group, equities research analysts anticipate that Exelixis, Inc. will post 3.42 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on EXEL. TD Cowen raised their target price on shares of Exelixis from $55.00 to $76.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Leerink Partners lifted their target price on Exelixis from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Thursday. Stifel Nicolaus lifted their target price on Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th. Wall Street Zen lowered Exelixis from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 1st. Finally, Zacks Research upgraded Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $58.85.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.